News Sentiment

NXTC sentiment intelligence

NextCure  Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.97 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Deals and strategy

74/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+4.8% over one week, -5.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Deals and strategy 74/100 classification
One-week reaction 4.8% Price confirming higher
Trend fit Trend inactive -5.1% over four weeks
Fair value -84.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 34
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
TradingView 10
Market source 6
simplywall.st 3
StocksToTrade 2
PR Newswire 2
GlobeNewswire 2
The Business Journals 1

Event Lens

What the news is about

Classified themes
Deals and strategy 20
Market update 18
Earnings 13
Guidance 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
Stock Titan Direct company coverage

NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan

NextCure (NASDAQ: NXTC) has detailed a proposed two-step merger with Avere Therapeutics, Inc., as per an Agreement and Plan of Merger and Reorganization dated July 14, 2026. The initial step involves Neptune Merger Sub Corp. merging into Avere, making Avere a wholly-owned subsidi

Tone
Positive 60/100
Event
Deals and strategy
Published
16 Jul 2026 21:12
Source
Stock Titan
The Business Journals Direct company coverage

Beltsville's NextCure merging with San Francisco startup

NextCure Inc., a Beltsville-based biotechnology company focused on cancer treatments, is merging with San Francisco startup Avere Therapeutics in an all-stock deal. NextCure had not yet brought a product to market. The acquisition includes United Therapeutics buying a biotech fir

Tone
Negative 40/100
Event
Deals and strategy
Published
15 Jul 2026 11:15
Source
The Business Journals
StocksToTrade Direct company coverage

NextCure (NXTC) Slides As Avere Merger Triggers Legal Scrutiny

NextCure (NXTC) stock has slid by over 12% following news of its merger with Avere Therapeutics, triggering legal scrutiny from multiple investor-rights firms. Shareholders of NextCure are set to own only about 1.21% of the combined company, with a contingent value right for 90%

Tone
Negative 30/100
Event
Deals and strategy
Published
15 Jul 2026 10:05
Source
StocksToTrade
TradingView Direct company coverage

NextCure to Merge With Avere in Stock Deal; $320 Million PIPE to Fund Combined Company

NextCure has signed a definitive merger agreement with Avere Therapeutics in a stock-for-stock transaction, which will result in Avere holders owning approximately 98% of the combined company, to be renamed Avere Therapeutics. To finance the merger, Avere secured a $320 million p

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jul 2026 09:10
Source
TradingView
TipRanks Direct company coverage

NextCure Announces Transformative All-Stock Merger With Avere

NextCure (NXTC) announced an all-stock merger with Avere Therapeutics, creating Avere Therapeutics on Nasdaq under the ticker AVRX. Avere holders and PIPE investors will own 98-99% of the new company, with NextCure shareholders receiving 1-2% plus contingent value rights from leg

Tone
Negative 37/100
Event
Deals and strategy
Published
15 Jul 2026 08:43
Source
TipRanks
Scrip Direct company coverage

Avere, NextCure Merge To Take AVR-001 Ahead In Psoriasis, Ulcerative Colitis

Avere and NextCure are merging to advance the development of AVR-001, an oral peptide IL-23 receptor antagonist. This reverse merger aims to target psoriasis and ulcerative colitis with the investigational drug. The companies anticipate that this strategic combination will facili

Tone
Positive 70/100
Event
Deals and strategy
Published
14 Jul 2026 21:42
Source
Scrip
PR Newswire Direct company coverage

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)

Monteverde & Associates PC, a class action law firm, has announced an investigation into NextCure, Inc. (NASDAQ: NXTC) regarding its proposed merger with Avere Therapeutics, Inc. The firm is questioning whether the deal, which would leave current NextCure shareholders owning appr

Tone
Negative 30/100
Event
Deals and strategy
Published
14 Jul 2026 17:42
Source
PR Newswire
StocksToTrade Direct company coverage

NextCure Inc. (NXTC) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live stock quotes and charts for NextCure Inc. (NXTC) on NASDAQ, showing its current price of $5.19, a decrease of $1.39 (-21.10%). The article notes that earnings information is not currently available and there are no analyst ratings within the last three mon

Tone
Negative 28/100
Event
Earnings
Published
14 Jul 2026 16:42
Source
StocksToTrade
PR Newswire Direct company coverage

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating NextCure (NASDAQ: NXTC) for potential breaches of fiduciary duty related to its transaction with Avere Therapeutics. Under the merger terms, NextCure stockholders will hold approximately 1.21% of the combined company, and receive a contingent value righ

Tone
Negative 34/100
Event
Deals and strategy
Published
14 Jul 2026 15:42
Source
PR Newswire
Business Wire Direct company coverage

NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of NextCure, Inc. (NASDAQ: NXTC) with Avere Therapeutics, Inc. The firm is concerned that NextCure and its board may have violated federal securities laws or breached fiduciary duties by not securing the b

Tone
Negative 40/100
Event
Deals and strategy
Published
14 Jul 2026 14:42
Source
Business Wire
Investing.com Direct company coverage

NextCure to merge with Avere Therapeutics in $320M deal

NextCure, Inc. has announced an all-stock merger agreement with privately-held Avere Therapeutics, Inc., valued at $320 million, which includes a concurrent private placement. Upon completion, the combined entity will operate as Avere Therapeutics, Inc. and trade under AVRX on Na

Tone
Positive 71/100
Event
Deals and strategy
Published
14 Jul 2026 10:42
Source
Investing.com
Seeking Alpha Direct company coverage

NextCure to merge with privately-held Avere (NXTC:NASDAQ)

NextCure (NXTC) announced an all-stock merger agreement with privately held Avere Therapeutics, a biotech company specializing in inflammatory diseases. This news caused NextCure's shares to surge over 200% in premarket trading. The combined entities also revealed a $320 million

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 Jul 2026 10:42
Source
Seeking Alpha
Stock Titan Direct company coverage

Avere anticipates early 2027 Phase 2b start for oral psoriasis therapy

NextCure (Nasdaq: NXTC) and Avere Therapeutics announced an all-stock merger to advance Avere's oral IL-23 program, AVR-001, for inflammatory diseases. The combined company, to be named Avere Therapeutics ("AVRX"), secured $320 million in private financing, including $251 million

Tone
Negative 30/100
Event
Deals and strategy
Published
14 Jul 2026 09:42
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of NextCure, Inc. – NASDAQ:NXTC

This article displays the enterprise value to EBITDA forward for NextCure, Inc. (NASDAQ: NXTC), as found on TradingView. It appears to be a financial data point within a larger platform, with no additional textual analysis or context provided in the snippet. The content primarily

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 19:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of NextCure, Inc. – MUN:2US0

This article focuses on the enterprise value to EBITDA forward for NextCure, Inc. (MUN:2US0). It provides a financial metric within the context of the company's trading information on the Munich Stock Exchange, highlighting that the market is currently closed with no trades.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 04:41
Source
TradingView
Quartr Direct company coverage

NextCure (NXTC) H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference summary

NextCure (NXTC) presented its lead candidate, NC-181, a humanized monoclonal antibody targeting APOE for Alzheimer's disease, at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. Preclinical studies indicate NC-181 reduces amyloid pathology and improves vascul

Tone
Positive 67/100
Event
Market update
Published
09 Jul 2026 06:41
Source
Quartr
Moomoo Direct company coverage

NextCure Company Profile & Introduction

This document provides a company profile and introduction for NextCure. It is likely a brief overview intended to present key information about the company.

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 19:10
Source
Moomoo
Finviz Direct company coverage

NXTC - Nextcure Inc Options

This article provides a detailed financial overview of Nextcure Inc (NXTC), including its stock performance, key financial metrics, and insider/institutional ownership. The company's stock recently closed at $2.14, showing a 13.71% increase for the day. Financial data highlights

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 18:11
Source
Finviz
TradingView Direct company coverage

Price to book forward of NextCure, Inc. – NASDAQ:NXTC

This article provides financial information for NextCure, Inc. (NASDAQ: NXTC), focusing on its forward price-to-book ratio. The content appears to be a stub or a placeholder from a financial data platform, indicating the company's stock market status and various financial and com

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 01:09
Source
TradingView